The global orthobiologics market is projected to grow from USD 6.68 billion in 2025 to USD 9.52 billion by 2031, with a CAGR of 6.17%. Growth is driven by rising osteoarthritis cases, sports-related injuries, and advancements in regenerative therapies including stem cell therapy and platelet-rich plasma treatments. North America leads the market while Asia-Pacific is the fastest-growing region.
Zimmer Biomet Holdings, Inc. (ZBH)
Common Stock · Currency in USD · XNYS
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Company Info
SIC3842
Composite FIGIBBG000BKPL53
CIK0001136869
IPOAug 7, 2001
Sectororthopedic, prosthetic & surgical appliances & supplies
Highlights
Market Cap$17.78B
EPS$4.68
P/E Ratio19.23
Revenue$8.16B
Gross Profit$5.77B
Net Income$924.80M
Employees17,000
WSO195,652,004
Phone(574) 267-6131
Websitehttps://www.zimmerbiomet.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Zimmer Biomet Holdings, Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Zimmer Biomet Holdings, Inc. (ZBH) has returned 1.02% so far this year and -13.73% over the past 12 months. Looking at the last ten years, ZBH has achieved an annualized return of -1.68%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
ZBH
1M-3.77%
6M-10.04%
YTD1.02%
1Y-13.73%
5Y-11.63%
10Y-1.68%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Zimmer Biomet Holdings, Inc. (ZBH) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.22% | 13.55% | -7.12% | 0.41% | ||||||||
| 2025 | 2.83% | -3.41% | 7.79% | -8.03% | -10.22% | -0.36% | 0.86% | 15.93% | -6.83% | 1.75% | -2.38% | -7.36% |
| 2024 | 3.78% | -0.85% | 6.39% | -8.61% | -2.49% | -5.21% | 4.06% | 3.24% | -6.40% | -0.87% | 4.38% | -5.19% |
| 2023 | -0.05% | -3.62% | 5.04% | 7.47% | -7.91% | 14.16% | -4.59% | -9.12% | -6.18% | -6.23% | 11.28% | 3.74% |
| 2022 | -3.40% | 3.26% | 2.51% | -4.73% | -0.92% | -13.05% | 4.92% | -2.68% | -1.43% | 6.92% | 5.67% | 5.38% |
| 2021 | -1.28% | 5.29% | -2.99% | 10.67% | -5.70% | -5.10% | 1.19% | -8.31% | -2.92% | -2.96% | -16.68% | 4.81% |
| 2020 | -1.39% | -8.49% | -26.10% | 23.34% | 7.43% | -5.25% | 12.57% | 3.97% | -2.88% | -3.68% | 11.39% | 2.39% |
| 2019 | 6.45% | 7.69% | 2.23% | -4.12% | -7.44% | 3.17% | 13.75% | 2.96% | -0.64% | 0.63% | 4.17% | 2.82% |
| 2018 | 5.06% | -7.99% | -6.00% | 5.77% | -3.23% | -0.67% | 13.60% | -1.29% | 6.06% | -13.82% | 2.78% | -11.80% |
| 2017 | 13.92% | -1.46% | 3.87% | -1.91% | -0.40% | 7.29% | -5.96% | -6.19% | 2.29% | 3.67% | 4.64% | 2.84% |
| 2016 | 8.90% | 5.48% | -1.51% | 8.71% | -0.96% | 0.40% | -18.61% | -4.40% | 1.39% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Zimmer Biomet Holdings, Inc. (ZBH) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of ZBH compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Zimmer Biomet Holdings, Inc. volatility is 1.52%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 23.09B | 21.37B | 21.50B | 21.07B | 23.46B | 24.42B | 24.64B | 24.13B | 25.96B | 26.68B | 27.22B |
| Equity Attributable To Parent (USD) | 12.70B | 12.47B | 12.48B | 12.02B | 12.66B | 12.19B | 12.39B | 11.27B | 11.74B | 9.67B | 9.89B |
| Equity Attributable To Noncontrolling Interest (USD) | 8.10M | 8.10M | 7.70M | 6.70M | 5.70M | 5.20M | 4.70M | 4.80M | -300.00K | 1.00M | 1.50M |
| Equity (USD) | 12.71B | 12.48B | 12.49B | 12.03B | 12.67B | 12.20B | 12.39B | 11.28B | 11.74B | 9.67B | 9.89B |
| Noncurrent Liabilities (USD) | 7.80B | 6.44B | 6.15B | 6.68B | 7.32B | 9.66B | 8.80B | 10.43B | 11.21B | 14.63B | 15.71B |
| Other Current Liabilities (USD) | 1.80B | 1.88B | 2.03B | 1.67B | 2.76B | 1.91B | 2.73B | 1.80B | 2.43B | 1.79B | 1.07B |
| Wages (USD) | 477.10M | 373.20M | 417.10M | 336.20M | 357.00M | 319.50M | 314.10M | 260.30M | 255.20M | 225.80M | 265.90M |
| Accounts Payable (USD) | 303.00M | 194.60M | 410.60M | 354.10M | 351.20M | 330.00M | 400.90M | 362.60M | 330.20M | 364.50M | 284.80M |
| Current Liabilities (USD) | 2.58B | 2.45B | 2.86B | 2.36B | 3.47B | 2.56B | 3.44B | 2.42B | 3.02B | 2.38B | 1.62B |
| Liabilities (USD) | 10.39B | 8.89B | 9.01B | 9.04B | 10.79B | 12.22B | 12.25B | 12.85B | 14.23B | 17.01B | 17.33B |
| Other Non-current Assets (USD) | 11.05B | 10.05B | 9.97B | 9.70B | 10.26B | 10.23B | 10.58B | 10.00B | 11.06B | 11.20B | 10.55B |
| Intangible Assets (USD) | 4.72B | 4.60B | 4.86B | 5.06B | 6.30B | 7.06B | 7.26B | 7.68B | 8.35B | 8.79B | 8.75B |
| Fixed Assets (USD) | 2.21B | 2.05B | 2.06B | 1.87B | 2.02B | 2.05B | 2.08B | 2.02B | 2.04B | 2.04B | 2.06B |
| Noncurrent Assets (USD) | 17.97B | 16.69B | 16.89B | 16.64B | 18.57B | 19.33B | 19.91B | 19.70B | 21.45B | 22.02B | 21.36B |
| Other Current Assets (USD) | 2.83B | 2.44B | 2.22B | 2.28B | 2.49B | 2.63B | 2.34B | 2.17B | 2.43B | 2.70B | 3.61B |
| Inventory (USD) | 2.29B | 2.24B | 2.39B | 2.15B | 2.39B | 2.45B | 2.39B | 2.26B | 2.08B | 1.96B | 2.25B |
| Current Assets (USD) | 5.12B | 4.67B | 4.61B | 4.43B | 4.89B | 5.08B | 4.72B | 4.43B | 4.52B | 4.66B | 5.86B |
| Assets (USD) | 23.09B | 21.37B | 21.50B | 21.07B | 23.46B | 24.42B | 24.64B | 24.13B | 25.96B | 26.68B | 27.22B |
News and Insights
The Portnoy Law Firm has initiated an investigation into possible securities fraud at Zimmer Biomet Holdings following a 15.2% stock price decline on November 5, 2025. The drop occurred after the company reported Q3 2025 net sales of approximately $2 billion and lowered its full-year organic revenue growth forecast from 4.5% to 4.0%, citing weakness in Latin America, emerging markets, and slowdowns in the U.S. revision market for orthopedic procedures.
With 59% of S&P 500 companies reported, Q4 2025 shows 13% EPS growth and 8.8% revenue growth. Big Tech's massive capex spending on AI infrastructure ($185B for Alphabet, $200B for Amazon) has sparked concerns about free cash flow sustainability and SaaS disruption from AI agents. This week's earnings focus shifts to semiconductor and software companies to assess whether AI spending benefits the broader ecosystem or threatens traditional business models.
The global orthopedic implants market is projected to grow from USD 23.50 billion in 2025 to USD 33.20 billion by 2033, expanding at a CAGR of 4.43%. Growth is driven by rising musculoskeletal disorders, aging populations, technological advancements in biomaterials and minimally invasive procedures, and digital orthopedic solutions. However, high implant costs, strict regulatory requirements, and pricing pressures from healthcare providers remain key challenges.
The global arthroscopy devices market is projected to grow from USD 8.8 billion in 2024 to USD 11.8 billion by 2032, driven by rising incidence of joint disorders, sports injuries, aging populations, and technological advancements in minimally invasive surgical procedures. North America leads the market, with Asia-Pacific expected to witness the fastest growth.
Europe's foot and ankle devices market is projected to grow from USD 1.01 billion in 2024 to USD 1.72 billion by 2033 at a CAGR of 6.1%, driven by aging populations, rising musculoskeletal disorders, and advancements in minimally invasive techniques and 3D-printed implants. Key growth factors include expanding hospital and outpatient facility capabilities and Europe's leadership in sports-injury treatment.
The global Pedicle Screw Systems Market is projected to grow from $2.38 billion in 2025 to $3.71 billion by 2033, with a 5.76% CAGR, driven by rising spinal disorder prevalence and technological advancements in spine surgery.
Zimmer Biomet Holdings experienced a significant stock price drop after revealing distributor order cancellations in emerging markets and reducing its revenue forecast, prompting a shareholder investigation into potential securities law violations.
Trex Company reported disappointing Q3 2025 financial results, with net sales 5% below guidance and a sequential revenue decline of 26%. The company revised its 2025 sales growth to flat, causing significant stock price drop and prompting an investor investigation.
The global nailing systems market is projected to grow at a 5.4% CAGR from 2026 to 2032, reaching $654.49 Million by 2032, driven by rising orthopedic trauma cases, technological advancements, and increasing preference for minimally invasive surgeries.